Substance Use Disorders (SUD)
Substance use disorders (SUDs) are complex conditions marked by compulsive substance use despite negative consequences. Recent research is exploring the therapeutic potential of various psychedelics, including LSD, psilocybin, and MDMA, in treating these disorders to provide novel, effective treatment options.
What is Substance Use Disorders (SUD)?
Substance use disorder (SUD) is characterised by an inability to stop using substances such as alcohol, tobacco, or illicit drugs, despite adverse effects on psychological and physical health.
Individuals with SUD often exhibit cravings, altered thought patterns, and compulsive behaviour, often leading to socio-economic issues and significant health burdens.
SUD is associated with changes in brain structure and function, which contribute to distorted thinking and compulsive behaviours.
Current Treatments
Standard treatment for SUD includes a combination of medical detoxification, cognitive behavioural therapy (CBT), and medication. Current medications include Vivitrol for opioid dependence and various support therapies such as twelve-step programs.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Substance Use Disorders (SUD).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD Historical studies show promise, but modern evidence is still developing. | Medium | Moderate | Inconsistent |
| Psilocybin Recent trials indicate high efficacy in smoking cessation and general addiction treatment. | Large | High | Consistent |
| MDMA Preliminary trials suggest effective treatment for alcohol use disorders. | Medium | Moderate | Consistent |
| Ketamine Clinical trials show significant improvements in abstinence rates in SUD patients. | Large | Moderate | Consistent |
| Ibogaine Effective for opioid withdrawal but carries significant cardiovascular risks. | Medium | Low | Inconsistent |
Psilocybin and Substance Use Disorders (SUD)
Psilocybin is thought to alter neural connectivity associated with addiction through its action on serotonin receptors, particularly the 5-HT2A subtype. This shift can enhance introspection and facilitate behavioural changes that support recovery from substance use, evidenced by high cessation rates in trials.
MDMA and Substance Use Disorders (SUD)
MDMA enhances emotional processing and reduces fear responses, making it particularly useful in therapeutic settings. This drug may enable patients to confront traumatic experiences that contribute to their substance use, exemplified by significant decreases in alcohol consumption when used in therapy.
Ketamine and Substance Use Disorders (SUD)
As an NMDA receptor antagonist, ketamine promotes neuroplasticity and disrupts maladaptive neural circuits implicated in addiction. Its rapid onset of action allows for swift intervention in acute situations, making it a beneficial option in addiction therapy.
Ibogaine and Substance Use Disorders (SUD)
Ibogaine acts on various neurotransmitter systems and has been noted for its effectiveness in reducing opioid withdrawal symptoms. However, its potential cardiotoxicity necessitates careful medical oversight during treatment.
Ayahuasca and Substance Use Disorders (SUD)
The combination of DMT with MAOIs in ayahuasca promotes profound psychological experiences that participants often report as life-altering. Serotonergic activity in the brain during these experiences may help individuals re-evaluate their addictive behaviours and contribute to reduced substance use.
Key Insights
- 1
Psychedelics have shown potential to bring about significant changes in addictive behaviour and promote long-lasting recovery.
- 2
Early studies suggest that psychedelics like psilocybin can lead to cessation rates for smoking that outperform conventional therapies.
- 3
MDMA has demonstrated safety and significant reductions in alcohol consumption in clinical trials involving patients with alcohol use disorder.
- 4
Ketamine-assisted therapy has facilitated abstinence in individuals with cocaine and alcohol dependence.
- 5
Ibogaine has shown promise in treating opioid withdrawal symptoms, although it poses serious cardiovascular risks.
Industrial Landscape
Key players in this space include Awakn Life Sciences, which is exploring multiple psychedelics for SUD, MindMed, which is testing ibogaine derivatives for addiction treatment, and Universal Ibogaine focused on expanding clinic access for opioid addiction treatment.
Quick Indicators
\"Ongoing clinical evaluations are investigating Substance Use Disorders (SUD) as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Substance Use Disorders (SUD).